Verify any claim · lenz.io
Claim analyzed
Science“Spleen enlargement in the Bajau people is caused by a point mutation.”
The conclusion
The claim overstates the precision of what science has confirmed. While genetic variants at the PDE10A locus are strongly associated with enlarged spleens in the Bajau and functional studies support a causal role, the most recent high-authority research (Nature, 2025) explicitly states that a direct causal single nucleotide variant has not been confirmed. The mechanism may involve regulatory changes or other factors, making the specific "point mutation" framing unsupported by current evidence.
Based on 13 sources: 7 supporting, 1 refuting, 5 neutral.
Caveats
- The term 'point mutation' has a specific scientific meaning (a single nucleotide change), and the most current peer-reviewed evidence (Nature, 2025) explicitly states this has not been confirmed as the causal mechanism for Bajau spleen enlargement.
- PDE10A genetic variants are associated with spleen size differences, but 'variants' is a broad term that encompasses regulatory changes, insertions, deletions, and other alterations — not just point mutations.
- Popular-science articles loosely use the word 'mutation' in ways that do not correspond to the precise technical term 'point mutation,' creating a misleading impression of scientific certainty.
Get notified if new evidence updates this analysis
Create a free account to track this claim.
Sources
Sources used in the analysis
Using a comparative genomic study, we show that natural selection on genetic variants in the PDE10A gene have increased spleen size in the Bajau, providing them with a larger reservoir of oxygenated red blood cells.
The Bajau spleen enlargement is associated with selection on PDE10A, but subsequent studies have not confirmed a direct causal single nucleotide variant; instead, it may involve regulatory changes or other factors in the locus.
Functional experiments in mice confirm that PDE10A variants lead to reduced PDE10A expression and larger spleen size, supporting a causal role for this gene in the Bajau spleen enlargement phenotype.
The authors identified mutations in a gene called PDE10A in the genome of the Bajau people. This gene is associated with enlarged spleen size. Follow-up research published in 2021 showed that mice with lower levels of PDE10A protein had an enlarged spleen, similar to what was observed among the Bajau people.
The surprise finding led researchers from the University of Copenhagen and UC Berkeley to a genetic mutation that appears to have spread throughout the population to increase spleen size. This genetic variant upregulates thyroid hormone, which in mice has been linked to larger spleen size. 'We think the way it works is that the expression of this variant gene changes thyroid hormone release, which then has an effect on spleen size,' Nielsen said. 'Nothing is really known about the genetic basis of spleen size in humans, so it is hard to validate without further research.'
The researchers did find a promising gene: PDE10A, which is associated with spleen size. The researchers’ finding that spleen size among the Bajau is equally large in divers and non-divers suggests that spleen size is a genetic adaptation, and not the product of phenotypic plasticity.
The research found that there was a variant in the gene PDE10A, which controls thyroid hormone and can lead to larger spleens. This variant was often found to appear in Bajau people.
DNA analysis revealed another change that turned out to be one of the most frequent gene variations in the Bajau population. This was in a gene that helps to control levels of a hormone called T4, which is produced by the thyroid gland. This hormone... is also associated with larger spleen size in mice.
Speaking to the BBC, Melissa Ilardo, from Cambridge University, said they dive repeatedly for eight hours a day, spending about 60 percent of their time underwater. It turns out that it's not just their skills that help them achieve this, but also a unique genetic mutation—known as the 'sea nomad gene'—that also aids in their diving ability. They have extra large spleens.
Through a selection scan, we identified a genetic variant under selection in the Bajau in the gene PDE10A that is associated with spleen size, which we confirmed in a European cohort. PDE10A is involved in the regulation of thyroid hormone levels. In mice, it has been shown that low levels of the thyroid hormone T4 decrease spleen size.
The original 2018 Cell paper identified a PDE10A variant correlated with spleen size, but it described a specific site (likely a SNP or point mutation) under selection; however, later reviews note it is not proven as the direct cause, with ongoing debate on causality versus correlation.
But it's not just their skills that set them apart from the rest of us, but a mutation in their genes that allows them to do so - known as the 'sea nomad gene'. Furthermore, the tribe also have unusually large spleens that enable them to stay submerged for long periods of time. 'We believe that in the Bajau they have an adaptation that increases thyroid hormone levels and therefore increases their spleen size.'
The researchers collected saliva and ultrasound data from volunteers in each population to study their DNA and calculate spleen size. They narrowed DNA results to the top 25 genetic differences (usually the slightly different versions of a single gene called 'alleles') unique to the Bajau genomes. One allele difference in the Bajau increased thyroid hormone levels. This may regulate spleen size in human development and early childhood.
What do you think of the claim?
Your challenge will appear immediately.
Challenge submitted!
Expert review
How each expert evaluated the evidence and arguments
Expert 1 — The Logic Examiner
The claim asserts a specific causal mechanism — a "point mutation" — as the cause of Bajau spleen enlargement. The logical chain from evidence to claim is as follows: Sources 1, 3, 4, 6, and 7 establish that PDE10A genetic variants are associated with and functionally linked to enlarged spleen size in the Bajau, but the critical inferential gap is whether "variants" equals "point mutation" (a single nucleotide variant/SNP). Source 2 (Nature, 2025) directly and explicitly states that "subsequent studies have not confirmed a direct causal single nucleotide variant," and that regulatory changes or other locus-level factors may be responsible — this is a direct logical refutation of the specific claim. The proponent commits a fallacy of equivocation by treating the broad term "variants" (which encompasses regulatory changes, indels, and other alterations) as synonymous with "point mutation," and by treating popular-press language loosely using "mutation" as scientific confirmation of a point mutation specifically. Source 3's mouse functional data confirms a causal role for PDE10A variants in spleen enlargement, but does not confirm the mechanism is a point mutation in humans. The opponent's rebuttal correctly identifies this equivocation and correctly notes that Source 2's 2025 review post-dates and supersedes the 2018 uncertainty, while the proponent's counter-rebuttal incorrectly dismisses Source 2 as merely "cautious review language" when it makes a direct empirical claim about the absence of confirmed SNP causality. The claim is therefore misleading: there is strong evidence for a PDE10A genetic variant causing spleen enlargement, but the specific assertion that it is a "point mutation" is not logically supported and is directly contradicted by the most recent high-authority source.
Expert 2 — The Context Analyst
The claim uses the specific term "point mutation" (implying a single nucleotide variant/SNP as the direct causal mechanism), but the evidence reveals important nuance: while PDE10A variants are associated with Bajau spleen enlargement and functional mouse studies support a causal role for reduced PDE10A expression (Sources 1, 3, 4), Source 2 (Nature, 2025 — the most recent high-authority source) explicitly states that "subsequent studies have not confirmed a direct causal single nucleotide variant" and that regulatory changes or other locus factors may be involved, and Source 5 quotes the lead researcher acknowledging the mechanism remains unvalidated. The claim omits that (1) the genetic basis involves "variants" at the PDE10A locus whose precise molecular nature remains debated, (2) the causal mechanism may be regulatory rather than a classic coding point mutation, (3) the association is well-supported but the specific claim of a "point mutation" as the cause overstates scientific certainty — making the overall impression misleading even if the broader genetic adaptation story is real.
Expert 3 — The Source Auditor
The most authoritative sources here are Source 1 (PubMed/Cell, 2018, high-authority) which identifies a PDE10A genetic variant under selection associated with spleen size, Source 2 (Nature, 2025, high-authority) which explicitly states that "subsequent studies have not confirmed a direct causal single nucleotide variant" and that regulatory changes or other locus factors may be involved, and Source 3 (Nature, 2021, high-authority) which confirms PDE10A variants causally enlarge spleens in mice but uses the broad term "variants" — not "point mutation" specifically. The claim uses the precise term "point mutation" (i.e., a single nucleotide variant/SNP as the direct causal mechanism), and the most recent and reliable source (Source 2, Nature 2025) directly refutes this specific framing, while Source 3's mouse functional data supports a causal role for PDE10A variants broadly without confirming a point mutation specifically. Lower-authority sources (Sources 7, 8, 9, 12) loosely use "mutation" in a popular-science sense without scientific precision, and Source 13 (Institute for Creation Research) carries negligible scientific weight. The claim as stated — that spleen enlargement is caused by "a point mutation" — is misleading: credible, high-authority sources confirm a genetic variant in PDE10A is associated with and likely contributes to Bajau spleen enlargement, but the most current high-authority source explicitly denies confirmation of a direct causal single nucleotide variant, making the specific "point mutation" framing unsupported by the best available evidence.
Expert summary
The arguments
Two AI advocates debated this claim using the research gathered.
Argument for
Comparative genomics in the Bajau identifies genetic variants under selection in PDE10A that are associated with increased spleen size (Source 1, PubMed), and subsequent functional work shows that PDE10A variants causally reduce PDE10A expression and produce larger spleens in vivo (Source 3, Nature), which is exactly the expected mechanistic signature of a causal point (single-nucleotide) mutation affecting phenotype. Multiple independent summaries of this research explicitly describe the finding as a specific “mutation” in PDE10A linked to enlarged spleen size in the Bajau (Sources 4 and 5), so the weight of evidence supports that Bajau spleen enlargement is caused by a point-mutation-level genetic change in/at the PDE10A locus.
Your reliance on Source 3 is a critical logical leap — it confirms that PDE10A variants reduce expression and enlarge spleens in mice, but "variants" is a broad term encompassing regulatory changes, insertions, deletions, and other alterations, none of which are synonymous with a point mutation, and Source 2 (Nature, 2025) explicitly states that "subsequent studies have not confirmed a direct causal single nucleotide variant," directly dismantling your inference that functional mouse data validates a point mutation as the cause in Bajau humans. You also commit a fallacy of equivocation by treating popular summaries in Sources 4 and 5 that loosely use the word "mutation" as scientific confirmation of a point mutation specifically, when Source 5 itself quotes the lead researcher admitting "nothing is really known about the genetic basis of spleen size in humans, so it is hard to validate without further research" — hardly the authoritative confirmation your argument requires.
Argument against
The claim that Bajau spleen enlargement is caused by a "point mutation" is directly contradicted by Source 2 (Nature, 2025), which explicitly states that "subsequent studies have not confirmed a direct causal single nucleotide variant" and that the effect "may involve regulatory changes or other factors in the locus," undermining any assertion of a singular, proven point mutation as the cause. Furthermore, Source 5 (UC Berkeley VC Research) and Source 11 (LLM Background Knowledge) both acknowledge that the proposed mechanism — a PDE10A variant influencing thyroid hormone and spleen size — remains unvalidated and debated, with Source 5 directly quoting the lead researcher admitting "nothing is really known about the genetic basis of spleen size in humans, so it is hard to validate without further research," confirming that the claim of causation by a point mutation is premature and unsupported.
You're treating Source 2's cautious review language (“may involve regulatory changes”) as a refutation of point-mutation causality, but it doesn't negate the direct functional evidence that PDE10A variants reduce expression and enlarge spleens in vivo (Source 3, Nature), which is precisely a causal genotype-to-phenotype link at the variant level. And your appeal to Source 5's 2018 uncertainty is a chronological fallacy: it predates the 2021 functional confirmation (Source 3) and can't outweigh it, while Source 11 is explicitly non-authoritative background rather than primary evidence.